QGEN · Qiagen N.V.

QIAGEN’s Q1 2026 results reflect a mixed operational performance amid significant external headwinds. While profitability held up—adjusted operating income margin remained robust at 27.4% despite tariff and currency pressures—the top line missed expectations: net sales declined 1% at constant exchange rates versus the prior-year quarter, falling short of the stated outlook for at least 1% CER growth. This shortfall was driven primarily by a 5% CER decline in QuantiFERON sales, attributed to a sharp drop in immigration-related latent TB testing in the U.S. and Middle East—a structural demand shift QIAGEN characterizes as a 'rebasining' rather than a long-term deterioration. Compounding this, U.S. Life Sciences customers maintained cautious capital spending, contributing to a 6% CER decline in instrument sales and dampening overall diagnostic solutions growth. Conversely, Sample technologies delivered strong 9% CER growth ($170M), aided by Parse Biosciences’ early contribution and momentum in automated consumables and new platform rollouts (QIAsymphony Connect, QIAmini). QIAcuity and QIAGEN Digital Insights also posted solid growth, underscoring strength in core innovation pillars. Management explicitly cited these areas as offsetting QuantiFERON weakness, reinforcing strategic focus on automation and bioinformatics. The updated full-year 2026 guidance—lowering net sales growth to ~1–2% CER and adjusted diluted EPS to at least $2.43 CER—reflects sustained pressure from QuantiFERON, NeuMoDx discontinuation, and geopolitical uncertainty, though management expects sequential improvement in H2 2026 driven by new panel launches (e.g., QIAstat-Dx Gastrointestinal), Parse’s outperformance, and easing of prior-year comparisons. The $500M synthetic share repurchase completed in January reduced shares outstanding by ~5%, supporting EPS resilience despite revenue softness.